Lineage Cell Therapeutics, Inc. Forecasted to Post FY2026 Earnings of $0.06 Per Share (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Lineage Cell Therapeutics in a research report issued on Monday, May 6th. HC Wainwright analyst J. Pantginis expects that the company will earn $0.06 per share for the year. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.18 EPS.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last released its earnings results on Thursday, March 7th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.04. The business had revenue of $2.09 million for the quarter, compared to the consensus estimate of $4.74 million. Lineage Cell Therapeutics had a negative net margin of 240.20% and a negative return on equity of 31.95%.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $6.00 target price on shares of Lineage Cell Therapeutics in a research report on Monday, February 5th.

Lineage Cell Therapeutics Stock Down 7.9 %

LCTX opened at $1.16 on Thursday. Lineage Cell Therapeutics has a 12-month low of $0.84 and a 12-month high of $1.61. The firm has a market capitalization of $219.01 million, a PE ratio of -8.92 and a beta of 1.39.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. DCF Advisers LLC raised its position in shares of Lineage Cell Therapeutics by 14.5% in the fourth quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock valued at $103,000 after purchasing an additional 12,000 shares during the period. Rathbones Group PLC acquired a new position in Lineage Cell Therapeutics during the 3rd quarter worth $41,000. SG Americas Securities LLC increased its stake in shares of Lineage Cell Therapeutics by 61.6% in the fourth quarter. SG Americas Securities LLC now owns 30,889 shares of the company’s stock worth $34,000 after purchasing an additional 11,779 shares during the period. Finally, Fifth Third Wealth Advisors LLC bought a new stake in Lineage Cell Therapeutics during the 1st quarter valued at approximately $30,000. Institutional investors and hedge funds own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.